Latest Intelligence on Cardiovascular and Diabetes in Denmark

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Novo Nordisk: setback for inhaled insulin

Denmark-based Novo Nordisk has dropped its fast-acting mealtime inhaled insulin product AERx due to a lack of commercial potential, and will focus on long-acting inhaled formulations instead. The problems faced by Novo in marketing the drug, including low satisfaction levels and re-imbursement issues with healthcare providers will also apply to other companies developing inhaled insulin systems.

Published By Datamonitor
16 Jan 2008

« | 1 | » »|

No help is available.